Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002349076 | SCV002621397 | uncertain significance | Cardiovascular phenotype | 2024-01-27 | criteria provided, single submitter | clinical testing | The p.R124Q variant (also known as c.371G>A), located in coding exon 3 of the SCN3B gene, results from a G to A substitution at nucleotide position 371. The arginine at codon 124 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003094326 | SCV003020628 | uncertain significance | Brugada syndrome 7 | 2022-01-06 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 124 of the SCN3B protein (p.Arg124Gln). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant has not been reported in the literature in individuals affected with SCN3B-related conditions. This variant is present in population databases (rs201894537, gnomAD 0.003%). |